Cell Therapies Pty Ltd (Cell Therapies) and Viral Vector Manufacturing Facility Pty. Ltd. (VVMF) have co-signed a memorandum of understanding (MoU) to explore strategic collaboration opportunities aimed at strengthening the onshore development and manufacture of Advanced Therapy Medicinal Products (ATMPs).
This partnership underscores a shared commitment to expanding access to ATMPs for both Australian and International patients through clinical trials.
The MoU also affirms joint efforts to advance capabilities across Australia’s cell and gene therapy (CGT) sector – bolstering support for the growing global CGT market and driving innovation and manufacturing capacity for the Asia Pacific (APAC) region.
Bev Menner, Cell Therapies CEO, said: “This collaboration advances efforts to secure a fully integrated onshore value chain for advanced therapies in Australia enhancing patient access to cutting-edge treatments, reinforcing clinical trial and translational capabilities, and enabling export-readiness across the APAC region. Strategic investment in sovereign manufacturing capacity for CGTs and critical inputs positions Australia to compete in the global advanced therapies market.”
Stephen Thompson, VVMF CEO, said: “VVMF is proud to collaborate with Cell Therapies, Australia’s leading capability in cell therapy manufacturing. Our complementary strengths and services reinforce Australia’s unique biomanufacturing ecosystem and showcase why Australia is a premier destination for the development and production of cell and gene therapies. Together we are committed to improving outcomes for patients, customers, and partners across Australia, the APAC region, and globally.”
ATMPs are innovative medicines based on genes, cells, or tissue engineering. They are often complex, based on cutting-edge science involving living cells, and require specialised manufacturing capabilities and a highly skilled workforce. ATMPs offer new treatments or cures for various diseases, including cancer, neurodegenerative, and cardiovascular diseases.
About Cell Therapies
Cell Therapies Pty Ltd (Cell Therapies) is Australia’s leading contract development and manufacturing organisation (CDMO) dedicated exclusively to cell and gene therapies. With over two decades of experience, Cell Therapies supports the development, clinical translation, and commercial manufacture of advanced therapy medicinal products (ATMPs), including CAR T-cells, blood stem cells, dendritic cells, mesenchymal stromal cells, and iPSC-derived therapies. Cell Therapies deliver world-class GMP manufacturing, embedded in the healthcare system, with unmatched experience and agility in APAC.
About VVMF – Unlocking the Future of Medicine
Viral Vector Manufacturing Facility Pty. Ltd. (VVMF) is Australia’s only Contract Development Manufacturing Organisation (CDMO) dedicated to providing services in the research, design, development, and manufacture of viral vectors for advanced therapeutic applications. VVMF partners with researchers, clinicians, and bio-pharma companies to accelerate the path to market for cell and gene therapies to local patients. Viral vectors play a crucial role in delivering genetic material into cells and are central to innovative treatments in areas of medicine including cancers and rare diseases.
For further information please contact [email protected]
Download the PDF here: Cell Therapies and VVMF Press Release
